원문정보
초록
영어
Objective: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in patients with non-valvular atrial fibrillation (NVAF). Methods: It was retrospectively studied from September 2012 to April 2014 using the electronic medical records and the progress notes. Patients with NVAF (n=424) were evaluated on the medication use, prescribing preferences, adverse drug reactions (ADRs) and the availability of prescription reimbursement of dabigatran (n=210) and rivaroxaban (n=214). Results: Dabigatran was prescribed higher than rivaroxaban (23.3% versus 7.5%, p<0.001) in the neurology department, but rivaroxaban was prescribed higher compared to dabigatran in the cardiology department (87.4% versus 74.3%, p<0.001). Dabigatran was prescribed more than rivaroxaban in high risk patients with CHADS2 score ≥ 3 (44.3% versus 31.3%, p=0.006). Dabigatran patients seemed to have more ADRs than patients with rivaroxaban (25.2% versus 11.2%, p<0.001), but no serious thrombotic events and bleeding were found. Only 35.6% (n=151) were eligible for prescription reimbursement by the National Health Insurance (NHI). Bridging therapy (86, 31.5%) and direct-current cardioversion (57, 20.2%) were main reasons of ineligibility for reimbursement. Conclusion: Prescription preferences were present in choosing either dabigatran or rivaroxaban for patients with NVAF. Inpatient protocols and procedures considering patient-factors in NVAF need to be developed.
목차
INTRODUCTION
METHODS
Patients and setting
Drug use and prescribing preferences
Compliance
Adverse drug reactions
Prescription reimbursement
Statistical analysis
RESULTS
Patients’ demographics and characteristics
Drug use evaluation and prescription preferences
Adverse drug reactions
Prescription reimbursement
DISCUSSION
CONCLUSION
FUNDING
CONFLICT OF INTEREST
ACKNOWLEDGEMENT
REFERENCES
저자정보
참고문헌
- 1Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association네이버 원문 이동
- 2Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Data System Rev 2005;3: Art. No. CD001927.
- 3Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.네이버 원문 이동
- 4Trends in oral anticoagulation therapy among Korean patients with atrial fibrillation : the Korean atrial fibrillation investigation네이버 원문 이동
- 5Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran네이버 원문 이동
- 6Dabigatran versus warfarin in patients with atrial fibrillation.네이버 원문 이동
- 7Newly identified events in the RE-LY trial.네이버 원문 이동
- 8Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study네이버 원문 이동
- 9Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.네이버 원문 이동
- 10Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.네이버 원문 이동
- 11Apixaban versus warfarin in patients with atrial fibrillation.네이버 원문 이동
- 12Edoxaban versus warfarin in patients with atrial fibrillation.네이버 원문 이동
- 13Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial네이버 원문 이동
- 14Mismetti P, Laporte S. Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim 2008; 27(Suppl3):516-21.
- 15Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial네이버 원문 이동
- 16U.S. Food and Drug Administration. Pradaxa (dabigatran): drug safety communication - lower risk for stroke and death, but higher risk for GI bleeding compared to warfarin. page last Updated: 05/13/2014. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformati on/SafetyAlertsforHumanMedicalProducts/ucm397179.htm. Accessed August 26, 2016.
- 17Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology.네이버 원문 이동
- 18Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation.네이버 원문 이동